Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.68 |
| ▸ | MAOA | P21397 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962771 | 0.95 | MAOB (0.64) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL29369517 | 0.90 | MAOB (0.78) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL384341 | 0.90 | MAOB (0.78) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL10797158 | 0.89 | MAOB (0.72) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL5445458 | 0.85 | KDM4E (0.49) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL31088170 | 0.85 | KDM4E (0.49) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL3214018 | 0.85 | MAOB (0.63) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL29184830 | 0.85 | MAOB (0.70) | MAOBMAOAMAPTCYP2C9CYP2C19 | |
| SCHEMBL10612639 | 0.85 | MAOB (0.55) | MAOBSMN1; SMN2L3MBTL1 | |
| SCHEMBL6450099 | 0.85 | MAOB (0.65) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | MAOB 954/4885MAOA 1304/4885MAPT 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.